SCTX.US Scribe Therapeutics Inc. Common Stock
- Market cap
- USD 291M
- P/E
- -
- P/B
- -
- ROE
- -35.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SCTX.US undervalued?
Graham numberThe Graham number of Scribe Therapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scribe Therapeutics Inc. Common Stock fundamental analysis
No fundamental analysis for Scribe Therapeutics Inc. Common Stock yet.
Scribe Therapeutics Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution fo…
Full company profileScribe Therapeutics Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scribe Therapeutics Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 27.4M | 51.2M | 7.72M |
| Gross Profit | - | -9.62M | 5.66M |
| Operating Income | -42.8M | -26.1M | -43.6M |
| EBITDA | -32.3M | -19.4M | -35.9M |
| Net Income | -47.8M | -21.8M | -44.9M |
| EPS | -2.72 | -1.24 | -2.37 |
| Balance Sheet | |||
| Total Assets | 128M | 78.2M | 188M |
| Total Liabilities | 254M | 101M | 62.8M |
| Shareholders' Equity | -126M | -23.1M | 125M |
| Cash & Short-term Investments | 12.6M | 58.0M | 174M |
| Total Debt | - | 41.4M | 5.14M |
| Cash Flow | |||
| Operating Cash Flow | -45.2M | -45.2M | - |
| Capital Expenditure | 1.35M | 1.27M | 36.0K |
| Free Cash Flow | -46.6M | -46.5M | - |
| Ratios | |||
| ROE | - | - | -35.9% |
| ROA | -37.3% | -27.9% | -23.9% |
| Net Profit Margin | -174.3% | -42.6% | -582.1% |
| Debt to Equity | - | - | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scribe Therapeutics Inc. Common Stock dividends
Scribe Therapeutics Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Scribe Therapeutics Inc. Common Stock
- Insiders 20.67%
- Institutions 79.33%
- Public & others 0.00%
- Shares outstanding 18.9M
- Free float 6.39M
Top funds holding SCTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 1.31M | 6.89% | +0.58% | Oct 2026 |
| T. Rowe Price Health Sciences | 684K | 3.61% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 291K | 1.53% | +1,779.32% | Sep 2026 |
| iShares Russell 2000 ETF | 246K | 1.30% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 244K | 1.29% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 136K | 0.72% | 0.00% | Sep 2026 |
| ARK Genomic Revolution ETF A USD Acc | 74.9K | 0.40% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 56.2K | 0.30% | +11,148.80% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 53.0K | 0.28% | -0.38% | Oct 2026 |
| iShares Russell 2000 Value ETF | 43.3K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 43.2K | 0.23% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences Port | 40.3K | 0.21% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 29.7K | 0.16% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 29.2K | 0.15% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 23.5K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 19.2K | 0.10% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 18.7K | 0.10% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 17.9K | 0.09% | 0.00% | Sep 2026 |
| JHVIT Health Sciences I | 15.5K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 15.0K | 0.08% | 0.00% | Sep 2026 |
Top institutions holding SCTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sanofi | 500K | 2.64% | 0.00% | Sep 2026 |
| Davy Asset Management Limited | 40.9K | 0.22% | 0.00% | Sep 2026 |
| Rhumbline Advisers | 8.90K | 0.05% | 0.00% | Sep 2026 |
| Tema ETFs | 3.05K | 0.02% | 0.00% | Sep 2026 |
Scribe Therapeutics Inc. Common Stock company profile
- Company name
- Scribe Therapeutics Inc. Common Stock
- Ticker
- SCTX.US
- Exchange
- USA Stocks
- Listed since
- Jul 24, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 77
- Fiscal year end
- December
- Address
- 1150 Marina Village Pkwy, Alameda, CA, United States, 94501
- Phone
- 510 626 8587
- Website
- scribetx.com
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Scribe Therapeutics Inc. Common Stock management
10- Dr. Benjamin L. Oakes Ph.D.Co-Founder, President, CEO & Chairman · born 1989
- Mr. David L. Parrot M.B.A.CFO & Treasurer · born 1969
- Dr. Svetlana Lucas Ph.D.Chief Operating Officer · born 1972
- Dr. Jennifer A. Doudna Ph.D.Co-Founder & Scientific Advisor · born 1964
- Mr. Brett T. Staahl Ph.D.Co-Founder & VP of External Innovation
- Mr. David F. Savage Ph.D.Co-Founder & Scientific Advisor
- Mr. Richard Hector J.D., Ph.D.Head of Intellectual Property
- Ms. Chitra Sharma M.S.Senior Vice President of Development
- Mr. Sunny Mok M.B.A., Ph.D.Senior Vice President of Operations
- Stephen V. ThauSecretary